How can the use of antiendotoxin monoclonal antibodies be controlled? Newsletter Article 17 February 2013 Pages: 4 - 5
Exciting progress in the worlds of antibody and genetic engineering Newsletter Article 17 February 2013 Pages: 5 - 6
Simvastatin: a first-line drug in hypercholesterolaemia? Newsletter Article 17 February 2013 Pages: 7 - 8
ALG + HDMP: a financially sound option in aplastic anaemia Newsletter Article 17 February 2013 Pages: 9 - 9
Cefetamet pivoxyl measures up well in children with acute pyelonephritis Newsletter Article 17 February 2013 Pages: 9 - 9
Cell adhesion molecules offer exciting therapeutic possibilities Newsletter Article 17 February 2013 Pages: 10 - 10
Potential clinical use for Boehringer Ingelheim's epinastine … Newsletter Article 17 February 2013 Pages: 10 - 10
Nonpharmacological therapy wins against propranolol Newsletter Article 17 February 2013 Pages: 12 - 12
Captopril + hydrochlorothiazide ‘a treatment of choice’ in hypertension Newsletter Article 17 February 2013 Pages: 14 - 14
Mupirocin is highly effective in eradicating S. aureus nasal carriage Newsletter Article 17 February 2013 Pages: 15 - 15
Treatment of breast cancer: the present position and future directions Newsletter Article 17 February 2013 Pages: 16 - 16
Pfizer's sertraline: making its mark on depression Newsletter Article 17 February 2013 Pages: 17 - 17
Perioperative antibacterial prophylaxis inadequate Newsletter Article 17 February 2013 Pages: 17 - 17
Nebulised salbutamol safe in severe COAD despite concerns Newsletter Article 17 February 2013 Pages: 17 - 18
Nisoldipine in postpartum hypertension: encouraging preliminary results Newsletter Article 17 February 2013 Pages: 19 - 19
Can the risk of diabetic complications be reduced? Newsletter Article 17 February 2013 Pages: 19 - 19
Diffuse rash with transdermal fentanyl - first report Newsletter Article 17 February 2013 Pages: 21 - 21
Safety factors are a consideration in selecting preinduction agents for children Newsletter Article 17 February 2013 Pages: 21 - 22